8 completed, 6 recruiting, 4 terminated, 2 active not recruiting. 22 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 8, Recruiting 6, Terminated 4, Active not recruiting 2, Not yet recruiting 2 |
| Phase 2 | 8 | Completed 4, Active not recruiting 2, Recruiting 2 |
Follow mFOLFOX6: new trials by email Literature Review of mFOLFOX6 trials Research Report on mFOLFOX6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Genentech, Inc. | 388 | 2026-11-30 | 2026-11-10 |
| EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer EMB-01, Irinotecan, TAS-102 - Unresectable/Metastatic Colorectal Cancer | Phase 1 | Recruiting | Shanghai EpimAb Biotherapeutics Co., Ltd. | 120 | 2026-09-30 | 2026-10-16 |
| A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer Cetuximab, mFOLFOX6 - mCRC | Phase 1 | Not yet recruiting | Shanghai Henlius Biotech | 387 | 2026-06-30 | 2026-04-24 |
| A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab - KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | Kestrel Therapeutics, Inc. | 545 | 2026-04-21 | 2026-11-12 |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 665 | 2025-03-31 | 2026-06-02 |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations ALTA3263, cetuximab, mFOLFOX6 - Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Alterome Therapeutics, Inc. | 448 | 2025-03-05 | 2026-10-26 |
| Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients cadonilimab, Trastuzumab, XELOX - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Recruiting | Zhejiang Cancer Hospital | 90 | 2024-07-10 | 2024-10-21 |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine - Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 910 | 2024-06-28 | 2026-11-16 |
| A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors ginisortamab, trifluridine/tipiracil, mFOLFOX6 - Advanced Solid Tumors | Phase 1 / Phase 2 | Completed | UCB Biopharma SRL | 93 | 2020-07-09 | 2025-05-29 |
| A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors TST001, Nivolumab Injection [Opdivo], mFOLFOX6 - Advanced Cancer, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 150 | 2020-05-28 | 2026-09-29 |
| Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer nab-sirolimus - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Completed | Aadi Bioscience, Inc. | 60 | 2018-07-01 | 2024-01-02 |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer Bemarituzumab, Modified FOLFOX6 - Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic | Phase 1 | Completed | Five Prime Therapeutics, Inc. | 12 | 2017-11-30 | 2024-02-28 |
| PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer PDR001, bevacizumab, mFOLFOX6 - Metastatic Colorectal Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 1 | 2017-09-25 | 2021-10-12 |
| Lidocaine for Oxaliplatin-induced Neuropathy Lidocaine Hydrochloride, Placebo, FOLFOX regimen - Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 26 | 2017-09-15 | 2022-03-09 |
| Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors TSR-033, Dostarlimab, mFOLFOX6 - Neoplasms | Phase 1 | Completed | Tesaro, Inc. | 111 | 2017-08-08 | 2024-04-11 |
| A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors Monalizumab, Durvalumab, Cetuximab - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | MedImmune LLC | 383 | 2016-02-22 | 2026-06-15 |
| Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors CRLX101, Bevacizumab, mFOLFOX6 - Solid Tumors | Phase 1 | Terminated | NewLink Genetics Corporation | 41 | 2015-10-01 | 2020-05-28 |
| Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma Idelalisib, Nab-paclitaxel, mFOLFOX6 - Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma | Phase 1 | Terminated | Gilead Sciences | 16 | 2015-07-30 | 2021-04-02 |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer BKM120, mFOLFOX6 - Advanced Solid Tumors, Metastatic Colorectal Cancer | Phase 1 | Completed | UNC Lineberger Comprehensive Cancer Center | 17 | 2012-05-01 | 2017-04-26 |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors GDC-0980, bevacizumab, capecitabine - Solid Cancers | Phase 1 | Completed | Genentech, Inc. | 41 | 2011-07-01 | 2016-11-02 |
Showing 20 of 22. Sign in to see all of them.
Colorectal Neoplasms (11) · Neoplasm Metastasis (5) · Pancreatic Neoplasms (4) · Colonic Neoplasms (3) · Lung Neoplasms (3) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Rectal Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Cholangiocarcinoma (1) · Cold Hypersensitivity (1)
Genentech, Inc. (2) · Aadi Bioscience, Inc. (1) · Alterome Therapeutics, Inc. (1) · Amgen (1) · Boehringer Ingelheim (1) · Five Prime Therapeutics, Inc. (1) · Gilead Sciences (1) · Hoffmann-La Roche (1) · Kestrel Therapeutics, Inc. (1) · MedImmune LLC (1) · NewLink Genetics Corporation (1) · Novartis Pharmaceuticals (1) · Shanghai EpimAb Biotherapeutics Co., Ltd. (1) · Shanghai Henlius Biotech (1) · Tesaro, Inc. (1)
United States (17) · United Kingdom (4) · China (3) · France (3) · Spain (3) · Australia (2) · Belgium (2) · Italy (2) · South Korea (2) · Canada (1) · Germany (1) · Hungary (1) · Japan (1) · New Zealand (1)
Autumn McRee, MD (1) · Charlie Qi, MD (1) · Jieer Ying, MD (1) · NewLink Ge (1) · Simon Haroutounian, PhD (1)
PMID 26032776, PMID 36852723, PMID 38084840, PMID 38309722, PMID 40016550, PMID 41108088, PMID 41790032
2016 (1), 2017 (1), 2019 (1)